• Hematologic malignancies are a group of malignant cancers that affect the blood, bone marrow, and lymphatic system. Formulating diagnosis and treatment protocol for a patient requires comprehensive examination results, including complete blood count, bone marrow biopsy, imaging tests, cytogenetic tests, and molecular genetic tests.

• Molecular genetic testing involves examination at the DNA level. Changes in DNA can lead to alterations in gene function, which in turn may contribute to the development of tumors.

• AcornHema 521 genetic test report sequences the DNA from the sample you provide, analyses the data and generates corresponding test reports, unveil the changes at the DNA level of your tumor cells.

After receiving the AcornHema 521 genetic test report, you can discuss your condition with your doctor.

• NCCN, ELN, WHO, and other authoritative guidelines have all clearly stated the necessity of molecular-level testing for patients with hematologic malignancies in diagnosis and treatment.
• The test report can help the doctor identify the specific subtype of hematologic malignancy you have.
• The test report can assist the doctor in determining the severity of your disease and assessing the effectiveness of your treatment.
• The test report can assist physicians in formulating personalized treatment protocol for you, specifying treatment duration, costs, and so on.